What they found
Combined FUS-mediated blood-brain barrier disruption with docetaxel-loaded perfluorocarbon nanodroplets (62 nm diameter, >90% encapsulation efficiency) for glioblastoma treatment. Achieved 28-fold reduction in systemic clearance versus free drug and extended median survival to 36 days (vs. 20 days control) with 33% long-term survival. The dual approach of barrier opening plus targeted nanocarrier delivery proved synergistic.
Lateral connection
The blood-labyrinth barrier (BLB) protecting the inner ear is structurally analogous to the BBB. FUS-mediated transient BLB opening combined with drug-loaded nanocarriers could enable non-invasive delivery of gene therapy cargo (AAV or mRNA-loaded nanoparticles) to the cochlea without surgical round window access. The 62 nm nanodroplet size is within the range that could penetrate cochlear tissues. The 28-fold reduction in systemic clearance suggests this approach could dramatically reduce the AAV dose needed for cochlear transduction, addressing immunogenicity concerns.
Hypothesis suggested
FUS-mediated transient BLB opening combined with AAV-mini-STRC loaded in perfluorocarbon nanodroplets could achieve cochlear transduction without invasive surgical delivery, potentially enabling bilateral treatment and repeat dosing.
What could be computed
Finite element modeling of FUS propagation through temporal bone to the cochlea, predicting: (1) achievable focal pressures at the organ of Corti, (2) safety margins relative to hair cell damage thresholds, (3) optimal transducer geometry for cochlear targeting.
Links
Connections
[source]auto-indexed 2026-04-20 by strc-lit-watch